Bethesda, MD (July 9, 2024)—The National Foundation for Infectious Diseases (NFID) is pleased to announce the 2024-2025 NFID Board of Directors and updated slate of officers, including President Jeffery A. Goad, PharmD, MPH; President-Elect Monica M. Farley, MD; Vice President Kevin A. Ault, MD; and Secretary-Treasurer Kevin M. Rooney.
Jeffery A. Goad, PharmD, MPH, is a professor of pharmacy practice and associate dean of academic affairs at Chapman University School of Pharmacy. He is the first pharmacist to serve as NFID president. A nationally recognized expert on travel medicine and immunization across the lifespan, he has maintained an active practice in travel medicine and immunization services for more than 20 years.
“One of the biggest challenges in public health today is political and social polarization,” Goad said in a recent episode of the NFID podcast Infectious IDeas. “NFID has the reputation and reach to educate and raise awareness among the public and healthcare professionals, but if people don’t trust the messenger, they won’t trust the message no matter how well we craft it. I look forward to building on the NFID history of collaboration to build an even stronger team with diverse perspectives to amplify messages that resonate and regain public trust.”
Goad is serving as NFID liaison to the Meningococcal Work Group of the Advisory Committee on Immunization Practices (ACIP).
Monica M. Farley, MD, is a professor of medicine and director of the Division of Infectious Diseases at Emory University School of Medicine. She is a past president of the American Federation for Medical Research and the Southern Society for Clinical Investigation. She serves as the principal investigator for the Georgia Emerging Infections Program (EIP), a Centers for Disease Control and Prevention (CDC)-funded surveillance network of epidemiologic and clinical research groups focused on invasive bacterial pathogens, influenza, and foodborne diseases. Farley is an NFID subject matter expert on pneumococcal disease, Clostridioides difficile infections, and community-associated methicillin-resistant Staphylococcus aureus (MRSA) disease.
Kevin A. Ault, MD, is a professor and chair of obstetrics and gynecology at Western Michigan University Homer Stryker MD School of Medicine. He served as a voting member of ACIP during the COVID-19 pandemic and was an author of the 2023 adult, adolescent, and pediatric US immunization schedules, which include recommendations for maternal immunization and adult hepatitis B vaccination. He currently serves as NFID liaison to the ACIP Human Papillomavirus (HPV) Vaccine Work Group and the Respiratory Syncytial Virus (RSV) Pediatric/Maternal Work Group. Ault is an NFID subject matter expert on maternal immunization, gonorrhea, chlamydia, herpes, RSV, and HPV.
Kevin M. Rooney is president of Beacon Consulting Group where he works with biopharmaceutical companies to drive greater value by addressing strategic business opportunities and issues. Throughout his career, he has had an extensive track record of successful leadership roles in the biopharmaceutical industry, and has run a successful consulting firm for more than 15 years.
Other new NFID Directors include Sean T. O’Leary, MD, MPH, and Matthew M. Zahn, MD. Orin S. Levine, PhD, of Tin Horse LLC, has been re-elected to serve an additional 3-year term as NFID Director.
Sean T. O’Leary, MD, MPH, is a professor of pediatrics and infectious diseases at the University of Colorado Denver Anschutz Medical Campus and Children’s Hospital Colorado. He is also an investigator at Adult and Child Center for Outcomes Research and Delivery Science (ACCORDS) and director of the Colorado Children’s Outcomes Network (COCONet), a pediatric practice-based research network. His research focuses on prevention of vaccine-preventable diseases through understanding clinical, attitudinal, and infrastructural barriers to vaccination, and developing and testing interventions to address those barriers.
Matthew M. Zahn, MD, deputy health officer of the OC Health Care Agency, has worked in local public health for 20 years, including overseeing immunization and communicable disease control programs for a diverse county of 3.2 million residents. He led the public health response to community outbreaks of vaccine-preventable diseases including measles, mumps, meningococcal disease, hepatitis A, H1N1 influenza, pertussis, and COVID-19. Zahn also supervised his agency’s response to local outbreaks of multi-drug resistant organisms including Candida auris. He served as ACIP liaison for the National Association of County and City Health Officials and continues to serve as a pediatric infectious disease clinician at the Children’s Hospital of Orange County.
A complete list of the 2024-2025 NFID Board of Directors is below. This esteemed group of public health leaders officially began responsibilities on July 1, 2024. As the governing body, the Board of Directors establishes the strategic direction for NFID, ensures that annual goals are met, and provides financial oversight.
The NFID Board of Directors also expresses its appreciation to outgoing officers and Directors including Past President Patricia N. Whitley-Williams, MD, Secretary Ruth Lynfield, MD, and Director Sara E. Cosgrove, MD, MS for their leadership and contributions to NFID. Whitley-Williams will continue to serve as an NFID spokesperson and Lynfield will continue to represent NFID on the ACIP Work Group on Adult RSV.
2024-2025 NFID Board of Directors
- Kevin A. Ault, MD, (NFID Vice President) Western Michigan University Homer Stryker MD School of Medicine
- Oliver T. Brooks, MD, Watts Healthcare Corporation
- Monica M. Farley, MD, (NFID President-Elect) Emory University School of Medicine
- Jeffery A. Goad, PharmD, MPH, (NFID President) Chapman University School of Pharmacy
- Jean-Venable R. Goode, PharmD, Virginia Commonwealth University
- Kathleen H. Harriman, PhD, MPH, RN, California Department of Public Health
- Orin S. Levine, PhD, Tin Horse LLC
- Julie Morita, MD, Robert Wood Johnson Foundation
- Flor M. Muñoz, MD, MSc, Baylor College of Medicine
- Kathleen M. Neuzil, MD, MPH, (NFID Federal Liaison) Fogarty International Center, National Institutes of Health
- Sean T. O’Leary, MD, MPH, University of Colorado Denver Anschutz Medical Campus
- Kevin M. Rooney, (NFID Secretary-Treasurer) Beacon Consulting Group
- Patricia A. Stinchfield, RN, MS, CPNP, (NFID Immediate Past-President) University of Minnesota School of Nursing
- Matthew M. Zahn, MD, OC Health Care Agency
Ex-Officio:
- Marla Dalton, PE, CAE, NFID Executive Director and CEO
- Robert H. Hopkins, Jr., MD, NFID Medical Director
About the National Foundation for Infectious Diseases
Founded in 1973, the National Foundation for Infectious Diseases (NFID) is a non-profit 501(c)(3) organization dedicated to educating and engaging the public, communities, and healthcare professionals about infectious diseases across the lifespan. NFID has a 4-star rating from Charity Navigator and has earned a Platinum transparency seal from Candid/GuideStar. For more information, visit www.nfid.org.
Contact: Diana Olson, dolson@nfid.org
Recent Press Releases
Infectious Disease Experts Urge Vigilance in Response to Bird Flu Outbreaks
Bethesda, MD (December 19, 2024)—The current bird flu outbreak underscores the importance of maintaining strong public health systems. “Stay alert, but do not panic,” says…
New Collaboration Aims to Empower Black Communities to Help Protect against Preventable Respiratory Diseases
NFID partners with National Council of Negro Women Good Health WINs to raise awareness about COVID-19, flu, pneumococcal disease, and RSV
Leading Health Organizations Urge Flu Vaccination for Those at Higher Risk
During National Influenza Vaccination Week, experts encourage everyone age 6 months and older to get vaccinated to reduce risk of severe illness and hospitalization